Provenge is a $93,000 drug that has been shown to extend the lives of some advanced prostate cancer patients by an average of 4.1 months, to 25.8 months.

Each course is three infusions. We can then assume that each month of life in a person with advanced prostate cancer is valued around $23,000. 

The government is deciding this week whether or not Medicare will pay for this drug.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s